Evolent Health Inc. (NYSE:EVH) – Investment analysts at Leerink Swann issued their Q2 2017 earnings per share (EPS) estimates for shares of Evolent Health in a research report issued to clients and investors on Sunday. Leerink Swann analyst D. Larsen anticipates that the firm will post earnings per share of ($0.11) for the quarter. Leerink Swann currently has a “Buy” rating and a $24.00 price target on the stock. Leerink Swann also issued estimates for Evolent Health’s FY2018 earnings at $0.05 EPS.
Other research analysts also recently issued reports about the stock. Zacks Investment Research raised shares of Evolent Health from a “hold” rating to a “buy” rating and set a $28.00 target price for the company in a research report on Tuesday, October 11th. Jefferies Group set a $28.00 price objective on shares of Evolent Health and gave the stock a “buy” rating in a report on Tuesday, October 4th. Canaccord Genuity set a $30.00 price objective on shares of Evolent Health and gave the stock a “buy” rating in a report on Wednesday, September 28th. FBR & Co raised their price objective on shares of Evolent Health from $24.00 to $26.00 and gave the stock an “outperform” rating in a report on Friday, August 5th. Finally, William Blair reaffirmed an “outperform” rating on shares of Evolent Health in a report on Friday, September 30th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $27.83.
Evolent Health (NYSE:EVH) opened at 21.00 on Wednesday. Evolent Health has a one year low of $8.14 and a one year high of $26.84. The stock’s 50 day moving average is $21.39 and its 200 day moving average is $20.71. The firm’s market capitalization is $1.43 billion.
Evolent Health (NYSE:EVH) last announced its quarterly earnings results on Wednesday, November 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.02. The company earned $60.20 million during the quarter, compared to the consensus estimate of $58.35 million. Evolent Health had a negative net margin of 69.04% and a negative return on equity of 5.54%. The company’s revenue for the quarter was up 39.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.16) earnings per share.
In other Evolent Health news, CEO Frank J. Williams sold 251,481 shares of the firm’s stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $21.54, for a total value of $5,416,900.74. Following the completion of the transaction, the chief executive officer now directly owns 1,304,799 shares of the company’s stock, valued at approximately $28,105,370.46. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Michael D’amato purchased 10,000 shares of the business’s stock in a transaction on Monday, November 14th. The stock was purchased at an average cost of $17.18 per share, with a total value of $171,800.00. Following the completion of the acquisition, the director now owns 18,183 shares in the company, valued at $312,383.94. The disclosure for this purchase can be found here. 8.85% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in EVH. Blair William & Co. IL increased its position in shares of Evolent Health by 205.5% in the second quarter. Blair William & Co. IL now owns 341,570 shares of the company’s stock valued at $6,558,000 after buying an additional 229,748 shares during the last quarter. Swiss National Bank increased its position in shares of Evolent Health by 90.2% in the second quarter. Swiss National Bank now owns 32,900 shares of the company’s stock valued at $632,000 after buying an additional 15,600 shares during the last quarter. Ameriprise Financial Inc. purchased a new position in shares of Evolent Health during the second quarter valued at approximately $1,565,000. Systematic Financial Management LP purchased a new position in shares of Evolent Health during the second quarter valued at approximately $3,480,000. Finally, Schwab Charles Investment Management Inc. increased its position in shares of Evolent Health by 1.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 42,784 shares of the company’s stock valued at $822,000 after buying an additional 504 shares during the last quarter. 37.14% of the stock is owned by hedge funds and other institutional investors.
About Evolent Health